The 2022 Tandem Meetings | Advances & unmet needs in APL
Firas El Chaer
• 23 Apr 2022
Firas El Chaer, MD, University of Virginia, Charlottesville, VA, comments on recent advances in acute promyelocytic leukemia (APL), highlighting remaining unmet needs in this field. Dr El Chaer first talks on the benefits of substituting anthracycline with gemtuzumab ozogamicin in the induction regimen of high-risk APL patients, and switching intravenous arsenic trioxide to an oral-based regimen. Dr El Chaer further underlines the importance of educating people about the symptoms of APL, as early ATRA treatment is critical to increase the chance of curing a patient. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
